Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU

NCT01859117 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral Arterial Disease
Diabetic Foot

Interventions

BIOLOGICAL: 3 x 10^6 cells
BIOLOGICAL: 10 x 10^6 cells
BIOLOGICAL: 30 x 10^6 cells
BIOLOGICAL: 100 x 10^6 cells

Sponsor

Celularity Incorporated